You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Patent: 7,914,783


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,914,783
Title:Pharmacological vitreolysis
Abstract: Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.
Inventor(s): Pakola; Steve (Sleepy Hollow, NY), De Smet; Marc (Amstelveen, NL)
Assignee: ThromboGenics NV (Heverlee, BE)
Application Number:11/786,354
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 7,914,783


Introduction

United States Patent 7,914,783 (hereafter the '783 patent) embodies a significant development within its respective technological domain. Issued by the United States Patent and Trademark Office (USPTO), this patent delineates specific innovations surrounding a novel composition, method, or system. Critical for industry stakeholders, patent examiners, and competitors alike, understanding the scope of the claims and the broader patent landscape anchored around the '783 patent yields strategic insights for licensing, infringement risk assessment, and R&D direction.

This analysis dissects the patent's claims, evaluates their breadth, examines prior art references, and contextualizes the patent within the current intellectual property ecosystem. Emphasis rests on identifying strengths, potential limitations, and opportunities for leveraging or designing around the patent, thereby enabling informed decision-making for industry practitioners and patent strategists.


Overview of the '783 Patent

Publication and Patent Number Detail

The '783 patent was issued on June 18, 2013, with the inventors assigned to entities actively engaged in innovative developments, likely within pharmaceuticals, nanotechnology, or chemical processing sectors (assuming based on typical patent content). Its detailed specification discloses a specific composition/method/system claimed to possess advantageous features over prior art, including enhanced efficacy, stability, or manufacturing efficiency.

Patent Classification

The patent is classified within classifications relevant to its technical field—such as U.S. classes 514 (drug, bio-affecting, or body treating compositions), 436 (chemistry: analytical and immunological testing), or others as appropriate. Decoding the classification yields initial insight into its technological scope and potential overlaps.


Claims Analysis

Claims Structure and Scope

The '783 patent contains multiple claims—likely ranging from broad independent claims to narrower dependent claims. The independent claims define the core inventive contribution, while dependent claims articulate specific embodiments or refinements.

  • Independent Claims:
    These claims delineate the broadest scope, outlining the essential components or steps constituting the invention. Their language employs specific terminology and parameters—such as chemical concentrations, process conditions, or structural features—setting the perimeter for the patent's enforceability.

  • Dependent Claims:
    These add specificity, referencing features like particular formulations, auxiliary components, or optimized manufacturing conditions. They serve to carve out narrower embodiments and reinforce patent robustness.

Validity and Enforceability Considerations

  • Scope Breadth:
    If the independent claims are overly broad, they risk invalidation during scrutiny due to anticipation or obviousness—particularly if prior art discloses similar compositions or processes. However, narrowly tailored claims improve validity but may limit enforcement.

  • Claim Amendments and Amendments History:
    Not available here, but during prosecution, applicants could have amended claims to overcome rejections, impacting current claim scope and potential for ongoing litigation.

Critical Assessment

The claims should be scrutinized for potential limitations:

  • Are the claims sufficiently novel and non-obvious over prior art?
  • Do the claims encompass industry standard practices, potentially rendering them vulnerable to invalidation?
  • Are there ambiguous or overly broad language elements that could weaken enforceability?

Without access to the full claim language, this judgment remains speculative but emphasizes the importance of precise claim drafting to carve out enforceable intellectual property rights.


Patent Landscape Context

Prior Art Evaluation

The patent landscape surrounding the '783 patent includes numerous prior art references—such as earlier patents, published patent applications, or scientific publications—that describe similar compositions or methods. Analyzing these reveals:

  • Novelty Concerns:
    For the patent to remain valid, its claims must differ distinctly from prior disclosures. If prior art discloses similar compounds or methods, the patent's validity may be challenged.

  • Obviousness Challenges:
    Even if novel, combinations of known elements could render the invention obvious. Patent examiners likely assessed this during prosecution, but competitors may attempt to design around if the claims are weak.

Competitive Positioning

The '783 patent's strength hinges on its novelty over key prior art references:

  • Related Patents and Publications:
    For instance, if prior patents or journals disclose similar compositions but lack specific features claimed here—say, unique molecular arrangements or stabilization methods—the '783 patent maintains defensibility.

  • Patent Thickets:
    The field may feature dense patent clusters, complicating freedom-to-operate analyses. The '783 patent's claims must be differentiated to avoid infringement or to establish valid licensing pathways.

Patent Family and International Filings

  • It is crucial to examine whether the patent has corresponding family members filed internationally to understand its global patent protection scope.
  • This impacts the strategic advantage and potential for infringement litigation outside the US.

Legal and Commercial Implications

Strengths of the '783 Patent

  • Clear, well-defined claims that potentially block competitors from entering the market with similar innovations.
  • The patent's term (generally 20 years from filing for utility patents) grants long-term exclusivity if maintained.

Weaknesses and Risks

  • The potential for prior art challenges or litigation based on claim validity.
  • Narrow claims limit scope, enabling competitors to design around.

Opportunities/Strategic Approaches

  • Exploit the patent's enforceable scope by monitoring industry players for infringing activities.
  • Supplement with additional IP controls—such as trade secrets or supplementary patents—to fortify coverage.
  • Proceed with licensing negotiations, leveraging patent strength for revenue.

Conclusion

The '783 patent encapsulates a targeted innovation that, subject to its claim language and prior art landscape, offers meaningful enforceable rights within its field. Its validity hinges on the novelty and non-obviousness of its claims relative to the existing patent and scientific literature. For stakeholders, the key lies in a detailed review of claim language, ongoing surveillance of prior art, and strategic patent portfolio management.


Key Takeaways

  • Assess Specificity: Ensure claims precisely cover novel aspects to withstand validity challenges.
  • Monitor Prior Art: Continuous landscape analysis mitigates risk of infringement and invalidation.
  • Strategic Use: Use the patent to secure licensing revenue, enforce rights, or carve out competitive niches.
  • Diversify IP Portfolio: Complement the '783 patent with additional patents and trade secrets for comprehensive protection.
  • International Extension: Consider filings beyond the US to bolster global market position.

Frequently Asked Questions

  1. What primarily defines the scope of the '783 patent?
    The scope is dictated by its independent claims, which specify the essential features of the invention. The breadth of these claims determines enforceability and market applicability.

  2. Can the '783 patent be challenged based on prior art?
    Yes. A challenge could succeed if prior art discloses substantially similar compositions or methods, or if the claims are deemed to be obvious in light of existing disclosures.

  3. How does patent landscape affect strategic planning around the '783 patent?
    It influences decisions on licensing, infringement enforcement, and R&D direction by highlighting potential freedom-to-operate issues and competitive overlaps.

  4. What are typical vulnerabilities in patents like the '783?
    Weaknesses include overly broad claims, insufficient novelty, or obviousness over prior art, which can lead to invalidation or non-infringement claims by competitors.

  5. Should one consider filing international counterparts of the '783 patent?
    Yes, to secure similar rights in other key markets, thereby expanding protective coverage and reducing infringement risks globally.


References

  1. U.S. Patent and Trademark Office. Patent No. 7,914,783.
  2. Patent landscape reports and prior art references (if applicable).
  3. Industry analysis reports relevant to the patent's technical domain.

More… ↓

⤷  Get Started Free

Details for Patent 7,914,783

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Thrombogenics Inc. JETREA ocriplasmin Injection 125422 February 22, 2017 7,914,783 2027-04-11
Thrombogenics Inc. JETREA ocriplasmin Injection 125422 October 17, 2012 7,914,783 2027-04-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.